ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Nichi-Iko Pharmaceutical Co., Ltd.

Business Summary

Nichi-Iko Pharmaceutical Co., Ltd. engages in the manufacturing, sales, distribution, export, import and related activities for various types of pharmaceutical products. The company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems and others. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue188,218M1,774.68M
Gross Profit21,245M200.31M
Operating income-10,119M-95.41M
Income before tax1,068M10.07M
Net income-4,180M-39.41M
EBITDA3,098M29.21M
Diluted EPS-65.27-0.61
Dividends Per Share250.23
Total Assets363,572M3,290.24M
Total liabilities251,134M2,272.70M
Total equity111,167M1,006.03M
Operating cash flow5,006M47.20M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 149,263M 164,717M 166,592M 190,076M 188,218M
Gross Profit 37,611M 40,803M 33,158M 37,320M 21,245M
Operating income 10,026M 13,200M 7,221M 7,572M -10,119M
Income before tax 5,963M 9,067M 8,903M 7,396M 1,068M
Net income 4,796M 8,069M 6,864M 5,133M -4,180M
EBITDA 17,091M 22,179M 16,987M 19,443M 3,098M
Diluted EPS 84.08 142.92 114.03 80.12 -65.27
Dividends Per Share 30 30 30 30 25
Total Assets 268,900M 278,364M 306,838M 336,819M 363,572M
Total liabilities 185,725M 190,819M 190,511M 219,644M 251,134M
Total equity 83,171M 87,542M 116,323M 115,827M 111,167M
Operating cash flow -4,076M 18,925M 23,811M 18,450M 5,006M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 1,378.39M 1,486.18M 1,502.25M 1,748.21M 1,774.68M
Gross Profit 347.32M 368.15M 299.00M 343.24M 200.31M
Operating income 92.58M 119.09M 65.11M 69.64M -95.41M
Income before tax 55.06M 81.80M 80.28M 68.02M 10.07M
Net income 44.28M 72.80M 61.89M 47.21M -39.41M
EBITDA 157.82M 200.11M 153.18M 178.82M 29.21M
Diluted EPS 0.77 1.28 1.02 0.73 -0.61
Dividends Per Share 0.27 0.27 0.27 0.27 0.23
Total Assets 2,413.17M 2,617.43M 2,772.17M 3,119.99M 3,290.24M
Total liabilities 1,666.74M 1,794.25M 1,721.19M 2,034.58M 2,272.70M
Total equity 746.39M 823.14M 1,050.93M 1,072.91M 1,006.03M
Operating cash flow -37.64M 170.75M 214.71M 169.69M 47.20M

Valuation Measures

Mar 2021
PER--
ROA-1.19%
ROE-3.68%
Operating margin-5.37%
Profit margin-2.22%

Key executives

  • President & Representative Director: Yuichi Tamura
  • Finance Manager: Naoyuki Okada
  • Head-Compliance Management & Guidance: Yasutomo Sai
  • Director, VP, Head-CSR, ESG & Business Creation: Kenji Akane
  • Executive Officer & Personnel Manager: Keiichi Arakawa

Shareholders

  • TAMURA YUICHI /NICHI IKO PHARMACEUTICAL/ (13.0%)
  • Hokuhoku Financial Group, Inc. (4.3%)
  • Nomura Asset Management Co., Ltd. (2.6%)
  • The Vanguard Group, Inc. (2.0%)
  • Dimensional Fund Advisors LP (1.5%)
  • Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.5%)
  • Nipro Corp. (1.4%)
  • Nichi-Iko Pharmaceutical Co., Ltd. (1.4%)
  • Nikko Asset Management Co., Ltd. (1.2%)
  • Daiwa Asset Management Co. Ltd. (1.2%)

Contact Details

Related Companies

  • Nichi-Iko Gifu Plant Co., Ltd.
  • Nichi-Iko Pharma Tech Co., Ltd.
  • Elmed Co., Ltd.
  • Nichi Iko Pharmaceutical Trust
  • SterRx LLC
  • Nichi-Iko Pharmaceutical Employee Incentive Plan
  • Nichiiko Pharma KK
  • Nichiiko Osaka KK
  • Yakuhan Pharmaceutical Co., Ltd.
  • Sagent Pharmaceuticals, Inc.
  • Kobayashi Pharmaceutical Industries Co. Ltd.
  • Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
  • Oriental Pharmaceutical Co., Ltd.
  • Teikoku Medix Co., Ltd.
  • Japan Galen, Inc.
  • Maruko Pharmaceutical Co. Ltd.
  • Nichiiko Pharmaceutical Employee Stock Pwnership Plan

Competitors

  • Dr. Reddy's Laboratories Ltd.
  • Cumberland Pharmaceuticals Inc.
  • Amphastar Pharmaceuticals Inc
  • Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
Last Updated on 18 Jun, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more